Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyra Therapeutics (LYRA) Non-cash Items (2021 - 2024)

Lyra Therapeutics (LYRA) has disclosed Non-cash Items for 4 consecutive years, with $1.3 million as the latest value for Q3 2024.

  • On a quarterly basis, Non-cash Items fell 50.92% to $1.3 million in Q3 2024 year-over-year; TTM through Sep 2024 was $1.3 million, a 50.92% decrease, with the full-year FY2024 number at $2.8 million, down 55.44% from a year prior.
  • Non-cash Items was $1.3 million for Q3 2024 at Lyra Therapeutics, down from $1.4 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $12.9 million in Q1 2024 to a low of $57000.0 in Q1 2023.
  • A 4-year average of $3.2 million and a median of $1.9 million in 2022 define the central range for Non-cash Items.
  • Peak YoY movement for Non-cash Items: crashed 92.55% in 2023, then surged 22480.7% in 2024.
  • Lyra Therapeutics' Non-cash Items stood at $918000.0 in 2021, then plummeted by 58.82% to $378000.0 in 2022, then skyrocketed by 1575.66% to $6.3 million in 2023, then tumbled by 79.48% to $1.3 million in 2024.
  • Per Business Quant, the three most recent readings for LYRA's Non-cash Items are $1.3 million (Q3 2024), $1.4 million (Q2 2024), and $12.9 million (Q1 2024).